---
id: grafomed-spec-audit-2026-08-26
type: product_spec_audit
product_id: grafomed-v1
audited_spec: products/grafomed-v1/PRODUCT_SPEC.md
audited_spec_version: "0.2.0"
status: passed_for_executable_schema_implementation
auditor: ghost
orchestrator: mia
authority: javier
created_at: 2026-08-26T15:04:00-05:00
canonical_language: en
legacy_migration_performed: false
front_created: false
---

# Grafo Med v1 product-spec audit

## Verdict

**PASS for executable schema implementation and the first internal vertical
proof.** The architecture contract is now coherent enough to implement without
requiring another product-level decision interview.

This verdict does **not** validate medical content, route performance, learner
benefit, assessment validity, or public-release readiness. Those claims remain
untested until the first slice passes its promotion threshold and later
empirical evaluation is performed.

## Audit basis

The audit compared the product spec against:

- Javier's confirmed Grafo Med design decisions;
- `memory/decisions/grafomed-v1-foundation.md`;
- `memory/learnings/grafomed-original-audit.md`;
- the approved Grafo Med tag architecture and registry;
- the learning-route graph systems synthesis;
- the MIA workspace boot, authority, evidence, and audit rules.

The review tested boundary clarity, semantic separation, evidence sufficiency,
route explainability, learner-loop closure, promotion authority, rights,
privacy, versioning, and non-regression against the legacy failure modes.

## Findings and resolutions

| ID | Severity | Pre-audit finding | Resolution in spec 0.2.0 | Status |
|---|---|---|---|---|
| GM-AUD-001 | Critical | Four implementation-blocking decisions were still marked open. | Packet, route, learner state, promotion, and first-test contracts are explicit. | Closed |
| GM-AUD-002 | Critical | “Source-locked” had no sufficiency test, so a citation string could pass. | Ten required source-lock elements and claim coverage are binding. | Closed |
| GM-AUD-003 | Critical | The spec named learner state but did not prove that evidence could change the next route action. | A minimum state model and success/failure adaptation test are required. | Closed |
| GM-AUD-004 | Major | `GrafoMedSlicePacket` had subfolders but no identity or integrity manifest. | Folder-based packet plus `packet.yaml`, hashes, refs, gates, and snapshot identity. | Closed |
| GM-AUD-005 | Critical | Basic-science objects and mastery targets could be forced into clinical node types or mislabeled as decisions. | Basic-science types were added; `mastery_atom` was confirmed in a separate learning layer. | Closed |
| GM-AUD-006 | Major | Route generation was a feature name rather than an inspectable algorithm contract. | Deterministic traversal, hard constraints, ranking dimensions, explanation, and a manual gold route are required. | Closed |
| GM-AUD-007 | Critical | Promotion had named reviewers but no objective threshold or audit coverage. | Twelve promotion conditions and 100% first-packet audit coverage are binding. | Closed |
| GM-AUD-008 | Major | Packet promotion and future public release could be read as one lifecycle. | Lifecycle and release status are now separate axes; v0.1 is `internal_only`. | Closed |
| GM-AUD-009 | Major | Rights, patient-data, learner-state privacy, and synthetic-case labeling were incomplete. | Explicit rights, privacy, patient-data, and educational-use boundaries were added. | Closed |
| GM-AUD-010 | Major | One consolidated report could erase reviewer separation and create circular approval. | The dossier may be consolidated, but it must contain five separate review artifacts and no producer may self-approve. | Closed |

## Non-regression result

The audited contract now prevents the main legacy failure modes:

- no horizontal scaling before one end-to-end proof;
- no node count, schema validity, or graph density as a proxy for truth;
- no source-unlocked promotion;
- no untyped relations or tag-as-ontology shortcuts;
- no mixing learner state with medical truth;
- no black-box recommender before interpretable rules have been tested;
- no silent overwrite, legacy relabeling, or derived index as canonical truth;
- no producer-only audit for the first packet.

## Residual risks and implementation debt

These are real but are no longer product-spec ambiguities:

1. `schemas/` and `tests/` are not yet implemented.
2. The first source has not yet been selected and source-locked.
3. The reserved slice packet has not yet been constructed.
4. No route has yet been generated or compared with a gold route.
5. No learner-state transition, remediation branch, or transfer case has yet
   been executed.
6. Medical accuracy and educational quality remain unreviewed because no slice
   content exists.
7. Learning efficacy, retention, transfer, and psychometric validity remain
   unknown and cannot be inferred from a successful infrastructure test.

## Next gate

The next authorized unit of work is **executable contract construction**:

1. build the minimum JSON/YAML schemas and relation registry;
2. build validators and failing fixtures;
3. scaffold the reserved packet with `packet.yaml`;
4. select and lock the first core source;
5. execute the first vertical slice without expanding its scope.

The spec should be revised only if implementation reveals a true architecture
contradiction. Field-level details that satisfy the contract belong in schemas
and config, not in another product interview.
